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Abstract
Background: The therapeutic effect of inhaled corticosteroids (ICS) may be affected by the
metabolism of the drug in the target organ. We investigated the in vitro metabolism of
beclomethasone dipropionate (BDP), budesonide (BUD), ciclesonide (CIC), and fluticasone
propionate (FP) in human lung precision-cut tissue slices. CIC, a new generation ICS, is hydrolyzed
by esterases in the upper and lower airways to its pharmacologically active metabolite
desisobutyryl-ciclesonide (des-CIC).
Methods:  Lung tissue slices were incubated with BDP, BUD, CIC, and FP (initial target
concentration of 25 μM) for 2, 6, and 24 h. Cellular viability was assessed using adenosine 5'-
triphosphate content and protein synthesis in lung slices. Metabolites and remaining parent
compounds in the tissue samples were analyzed by HPLC with UV detection.
Results: BDP was hydrolyzed to the pharmacologically active metabolite beclomethasone-17-
monopropionate (BMP) and, predominantly, to inactive beclomethasone (BOH). CIC was
hydrolyzed initially to des-CIC with a slower rate compared to BDP. A distinctly smaller amount
(approximately 10-fold less) of fatty acid esters were formed by BMP (and/or BOH) than by BUD
or des-CIC. The highest relative amounts of fatty acid esters were detected for BUD. For FP, no
metabolites were detected at any time point. The amount of drug-related material in lung tissue
(based on initial concentrations) at 24 h was highest for CIC, followed by BUD and FP; the smallest
amount was detected for BDP.
Conclusion: The in vitro metabolic pathways of the tested ICS in human lung tissue were differing.
While FP was metabolically stable, the majority of BDP was converted to inactive polar metabolites.
The formation of fatty acid conjugates was confirmed for BMP (and/or BOH), BUD, and des-CIC.
Background
Inhaled corticosteroids (ICS) are the standard first-line
anti-inflammatory therapy for the management of persist-
ent asthma [1]. ICS increase pulmonary function and
decrease airway hyperresponsiveness, symptom severity,
acute exacerbations [2], hospitalizations, and asthma
mortality rates [3]. Binding of an ICS to the glucocorticoid
receptor in the lung leads to a pleiotropic reduction in the
expression of multiple pro-inflammatory pathways by
reversing histone acetylation of the activated genes [4,5].
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The preferred way to administer a corticosteroid in asthma
therapy is by inhalation. This route delivers drug straight
to the lung for local activity and minimizes the systemic
side effects associated with oral administration. Neverthe-
less, even treatment with ICS may cause both local and
systemic side effects. Deposition of the drug in the
oropharynx may cause local side effects, including
oropharyngeal candidiasis, dysphonia, reflex cough,
bronchospasm, and pharyngitis [6,7]. Direct absorption
of the active drug into the systemic circulation across the
mucosa of the oropharynx and airways or absorption of
swallowed drug via the gastrointestinal tract may result in
systemic side effects. Skin thinning and bruising, cataracts,
growth retardation, accelerated bone loss, and hypotha-
lamic-pituitary-adrenal axis suppression have been
observed in patients receiving long-term, high-dose ICS
treatment [8,9].
Pharmacokinetic (PK) properties of ICS are related to
safety and efficacy of the drug. The efficacy of an ICS is
dependent on high glucocorticoid receptor binding, high
pulmonary deposition and retention, enhanced
lipophilicity, and lipid conjugation. Safety is optimized
by low oral bioavailability, high protein binding, and
rapid systemic clearance [10,11]. Beclomethasone dipro-
pionate (BDP), budesonide (BUD), and fluticasone pro-
pionate (FP) are widely used ICS and have been on the
market in Asia, America, and Europe for several years.
Ciclesonide (CIC) is a novel, nonhalogenated ICS that has
been developed to incorporate PK properties that lead to
high efficacy and an improved safety profile [11-15]. The
prodrug CIC is administered as an inactive parent com-
pound to the lower airways, where it is converted to its
pharmacologically active metabolite desisobutyryl-cicle-
sonide (des-CIC) by endogenous esterases [12,16-19]
Des-CIC has a high affinity to the glucocorticoid receptor,
comparable with beclomethasone-17-monopropionate
(BMP), whereas BUD has a slightly lower and FP a higher
binding affinity [11]. Within the lung cells, des-CIC and
BUD undergo reversible esterification with fatty acids at
the C-21 position of the molecules. The formed fatty acid
conjugates may serve as a depot that slowly releases des-
CIC and BUD in the lung [16,20-23] Hydrolysis of BDP at
positions 17 and 21 results in three different metabolites,
ie BMP, beclomethasone-21-monopropionate (21-BMP),
and beclomethasone (BOH). BMP is the active metabo-
lite, whereas BOH and 21-BMP have a very low binding
affinity to the glucocorticoid receptor [11,24].
In the present study we investigated the in vitro metabo-
lism of BDP, BUD, CIC, and FP in the target organ lung,
using human lung precision-cut tissue slices, to evaluate
the major factors influencing the retention time of these
ICS in the lung.
Methods
Materials
BUD, CIC, des-CIC, des-CIC-palmitate, des-CIC-oleate,
and FP were synthesized by ALTANA Pharma AG, Kon-
stanz, Germany. BDP and BMP were obtained from MDS
Pharmaservices (Fehraltorf, Switzerland).
Waymouth's MB752/1 powdered medium without phe-
nol red was purchased from Gibco Laboratories (Grand
Island, NY, USA). Fetal bovine serum and Fungi-Bact solu-
tion were purchased from Irvine Scientific (Santa Ana, CA,
USA). Electrophoresis-grade agarose was obtained from
ICN Biochemicals (Cleveland, OH, USA), and tracheal
balloon catheters were obtained from Mallinchrodt Criti-
cal Care (Glen Falls, NY, USA). The dynamic roller culture
incubators, Brendel/Vitron tissue slicer, titanium roller
inserts, cordless coring tools, and V-7 cold preservation
solution were manufactured by Vitron, Inc. (Tucson, AZ,
USA). Water was Millipore filtered. All other reagents were
obtained from Merck (Darmstadt, Germany) and were of
professional analysis quality except methanol and etha-
nol, which were HPLC gradient grade.
Human tissue collection
The American Association of Human Tissue Users sup-
plied three lungs. The lungs were accepted by The Ameri-
can Association of Human Tissue Users from American
procurement agencies that followed donor consent proce-
dures according to accepted medical and ethical standards
as outlined by the Uniform Anatomical Gift Act. Tissues
were negative for infectious agents including HIV and
hepatitis. Organs were obtained under transplantation,
but were not viable for transplantation because of ana-
tomic irregularities, histological findings, age of donor,
time in transit, or health status of the recipient.
Preparation of tissue slices
Lung slices were prepared at Vitron, Inc. (Tucson, AZ,
USA) as previously described [25]. In brief, the lungs were
inflated with 2 to 4 L of 0.5% agar/Waymouth's medium
mixture at 37°C and were stored at 4°C for 30 to 60 min.
Each lung was cut into 2 cm thick slabs, placed on dental
wax, and tissue cylinders of 8 mm diameter were prepared
using a cordless coring tool. 400 μm thick slices were cut
from the cylinders using a Brendel-Vitron tissue slicer
[26].
Tissue incubation
Three lung slices from each donor were floated onto tita-
nium roller inserts, blotted, and loaded horizontally into
glass scintillation vials containing 1.7 mL of Waymouth's
MB752/1 tissue culture medium fortified with 10% fetal
calf serum, 0.35 g/L L-glutamine, 10 mL/L Fungi-Bact, and
84 μg/mL gentamicin sulfate.Respiratory Research 2007, 8:65 http://respiratory-research.com/content/8/1/65
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Three vials were used per substrate and time point. A stock
solution of the substrate was added prior to dispensing
the media into vials. The final substrate concentration was
25 μM. The vials were closed with caps that had central 2-
mm holes, placed in a Dynamic Organ Culture incubator
(Vitron, Inc., Tucson, AZ, USA) at 37°C, and exposed to
95% O2 and 5% CO2. The human tissue slices were incu-
bated for 2, 6, and 24 h, and cellular viability of human
lung slices was assessed using separate incubation sam-
ples (see assessment of cellular viability). Slices and media
from each vial were harvested separately into separate
tubes and stored at -80°C. Metabolism samples contain-
ing either tissue or media were shipped on dry ice from
Vitron, Inc. to ALTANA Pharma AG for analysis.
Assessment of cellular viability
Cellular viability was determined by measuring adenosine
5'-triphosphate (ATP) content and protein synthesis in
human lung tissue. ATP content was measured using a
luciferin-luciferase assay [27]. Tissue slices were homoge-
nized in 1 mL 10% trichloroacetic acid and were immedi-
ately frozen at -80°C until ATP content was measured
using a luminometer. Protein synthesis was measured by
the addition of 0.3 μCi [3H]-leucine/mL to tissue slice
incubations. Tissue slices were sonicated in 1 mL distilled
water, and a 20 μL aliquot was used to determine protein
content. The remaining homogenate was precipitated
with 5% (w/v) perchloric acid. Samples were centrifuged
and the resultant pellet was washed 3 times. The final pel-
let was dissolved in 0.5 mL of 0.5 N sodium hydroxide
and neutralized with 125 μL of 2 N hydrochloric acid.
Incorporation of the labeled amino acid into acid-precip-
itable material was measured by counting a 0.5 mL aliq-
uot of the sample in Bio-Safe II scintillation cocktail.
Viability of lung tissue slices was expressed per milligram
of protein.
Sample preparation
The volume of medium was measured at the end of the
incubation period. Samples of the incubation medium
were prepared by mixing 60 μL of medium with 60 μL of
solution for precipitation (0.2 M ZnSO4/ACN, 1:1). Fol-
lowing centrifugation for 5 min (1,000 × g Model5414,
Eppendorf) at room temperature, the supernatant was
assayed by high performance liquid chromatography
(HPLC). Tissue samples were homogenized in 1 mL of
methanol using ultrasonic treatment (Branson Sonifier
250; Branson Ultrasonics Corporation, Danbury, Conn)
and were centrifuged for 5 min (1,000 × g Model5414,
Eppendorf) at room temperature. After centrifugation,
333 μL of the supernatant was dried under a gentle stream
of nitrogen at 45°C and resuspended in 75 μL of metha-
nol before analysis.
High-performance liquid chromatography analysis
HPLC analysis was performed using a Hewlett-Packard
HP1090 liquid chromatograph (Agilent Technologies
Deutschland GmbH, Waldbronn, Germany) with an
ultraviolet (UV) detector monitoring at 242 nm. Separa-
tion was achieved using a Hypersil MOS column (125 × 4
mm, 5 μm) (Thermo Electron Corp., Dreieich, Germany).
A water/ethanol gradient system was run from 30 to 90%
ethanol in 10 min followed by an isocratic phase (6 min)
with 90% ethanol at a flow rate of 0.75 mL/min. 25 μL of
the tissue extract or 100 μL of the supernatant of the
medium were injected onto the column. This system was
suitable to assay all parent compounds used as substrate
and the fatty acid conjugated metabolites. BOH, BDP,
BMP, BUD, CIC, des-CIC, des-CIC-oleate, and FP were
used as reference compounds. All these compounds have
a similar UV response at 242 nm.
Results
Donor information
Human lung tissues from 3 human donors were used to
study metabolism of four ICS. Donor profiles are summa-
rized in Table 1.
Cellular viability
Viability of tissue samples was assessed using ATP content
and protein synthesis levels in human lung after incuba-
tion of tissue samples with ICS for 2, 6, and 24 h. ATP con-
tent ranged from 17.0 to 40.7 nmol/mg protein. Protein
synthesis displayed a linear mean increase from 1,930
dpm/mg protein after 2 h of incubation to 15,409 dpm/
mg protein after 24 h of incubation (Table 2). Fisher and
colleagues have reported that ATP content should exceed
10 nmol/mg protein and protein synthesis should be lin-
ear over time in viable human lung tissue [26]. Therefore,
all lung tissue samples used in this study were highly via-
ble.
Analytics
The HPLC system was suitable to assay all parent com-
pounds used as substrate as well as all known major
metabolites. However, the inactive 21-BMP was not avail-
able as reference compound. It was assumed that the
retention time of BMP and 21-BMP is similar and in some
cases shoulders in the BMP peaks were observed. Assum-
Table 1: Donor characteristics
D o n o r 123
Age 19 48 43
Sex Male Male Female
Race Hispanic Caucasian Caucasian
Cause of death Cerebrovascular Cerebrovascular Cerebrovascular
Medical history Healthy Healthy Healthy
Medications None None NoneRespiratory Research 2007, 8:65 http://respiratory-research.com/content/8/1/65
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ing coeluation of BMP and 21-BMP from the HPLC col-
umn and assuming a very similar UV response, the BMP
peak may represent partly 21-BMP. Therefore, the amount
of active BMP may be overestimated.
Furthermore, the lipophilic fatty acid conjugated metabo-
lites as well as the polar BOH were detectable. Matrix
peaks did not influence the detection of drug-related
peaks. Results of control samples confirmed the stability
of the tested compounds during incubation under the
used conditions. Furthermore, matrix peaks of tissue slices
and medium could be identified using the HPLC system.
Interday variability of all analytes was less than 15%.
Drug-related material in the incubation medium
Substrates were analyzed in medium after an incubation
time of 2, 6, and 24 h. BUD and FP were stable, ie no
metabolites were detected in medium, whereas the rela-
tive amounts of CIC and BDP decreased over time and
metabolites were detected in the incubation medium
(Table 3). CIC was metabolized to des-CIC, which was the
only metabolite of CIC in the medium. At the end of the
incubation period (24 h), the parent compound
accounted for 37% of CIC-related material in the
medium. In contrast, at 24 h of incubation, there was no
BDP detectable in the medium, whereas its metabolites
accounted for 91.6% (BOH) and 8.4% (BMP) of BDP-
related material (Table 3).
Drug-related material in tissue samples
In contrast to the medium samples, fatty acid esters were
detectable in tissue extracts. Furthermore, metabolic dif-
ferences between the ICS were obvious in tissue extracts.
The relative amounts of BDP, BUD, CIC, FP, and their
respective metabolites in human lung tissue at 2, 6, and
24 h of incubation are presented in Table 4. Absolute
amounts of the drugs and their metabolites are presented
in Figure 1 and Table 5.
BDP was hydrolyzed to active BMP and to pharmacologi-
cally inactive BOH and 21-BMP. As mentioned above, 21-
BMP could not be quantified due to coeluation in the
BMP peak and therefore the amount of active BMP may be
overestimated. BMP was the major metabolite at 2 h and
6 h, whereas BOH was the major metabolite at 24 h. At 24
h, BMP accounted for 26.6% and BOH for 64.9% of BDP-
related material. Fatty acid esters were formed by BMP
(and/or BOH), but the amount was distinctly smaller
(approximately 10-fold less) when compared with the
amount of fatty acid esters found for BUD and des-CIC.
The relative amount of BUD decreased over time and sim-
ilar amounts of BUD and its fatty acid esters were detected
in the tissue at 24 h. CIC was initially hydrolyzed to des-
CIC, which subsequently was conjugated with fatty acids.
Both the relative and the mean amounts of des-CIC and
fatty acid conjugates of des-CIC increased over time. For
FP, no metabolites were detected in the tissue extract. FP
was metabolically stable in this test system. Furthermore,
the intracellular amount of FP was similar at all time
points during incubation.
Based on these results, active metabolites were formed by
BDP and CIC. The enzymatic cleavage of BDP to BMP was
faster than the formation of des-CIC from CIC (see 2 h
data in Table 4). The active metabolite BMP was further
metabolized to BOH, whereas the active metabolite des-
CIC and the active compound BUD formed intracellular
fatty acid esters. These esters may serve as precursors of the
active compounds because the conjugation is a reversible
process. Parent compounds, active metabolites, and fatty
acid esters form a pool of active drug. At 24 h, the mean
absolute values for the active drug pools in the lung tissue
slices were 9.31 nmol for BDP, 17.95 nmol for BUD,
24.43 nmol for CIC, and 9.51 nmol for FP. The pool of
active drug (including parent compound, active metabo-
lite, and fatty acid esters) was larger for CIC than for the
other ICS.
Table 3: Relative drug amounts [% of total UV areas] in medium
Incubatio
n time [h]
Parent 
compound
Active 
compound
Inactive 
metabolite
Beclomethasone  2 60.9 ± 7.0 35.7 ± 6.4 3.4 ± 0.8
Dipropionate1 6 19.1 ± 8.3 53.5 ± 4.3 27.3 ± 4.7
24 - 8.4 ± 5.3 91.6 ± 5.3
Ciclesonide 2 94.9 ± 1.3 5.1 ± 1.3 -
6 83.2 ± 5.5 16.8 ± 5.5 -
24 37.4 ± 7.8 62.6 ± 7.8 -
Data are presented as mean ± standard deviation (n = 9).
No metabolites of Bud and FP were detected in medium.
1The active compound of BDP may be overestimated as inactive 21-BMP may be 
included.
Table 2: Viability parameters
Incubation 
time [h]
Lung 
from 
donor
ATP Content 
[nmoles ATP/
mg protein]
Protein 
Synthesis [dpm/
mg protein]
1 36.3 – 37.4 2,688 – 2,797
2 2 36.5 – 40.2 1,924 – 2,355
3 21.0 – 26.2 908 – 939
1 37.7 – 43.4 4,787 – 5,251
6 2 42.1 – 49.1 3,806 – 4,595
3 20.6 – 24.6 2,898 – 3,481
1 34.7 – 37.2 13,862 – 14,851
24 2 33.6 – 40.7 16,155 – 17,313
3 17.0 – 23.1 14,268 – 16,455
Data from n = 3 tissue slices per lung.Respiratory Research 2007, 8:65 http://respiratory-research.com/content/8/1/65
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Discussion
Several pharmacokinetic and pharmacodynamic parame-
ters, including bioavailability, receptor binding-affinity,
and elimination half-life contribute to the safety and effi-
cacy profile of an ICS. While developing topical corticos-
teroids for the treatment of asthma, a delicate balance
between safety and efficacy must be considered. In the
present study, differences in the in vitro metabolism of
currently available ICS in human lung tissue slices were
evaluated with respect to their local effect on pulmonary
residence time.
Results of the present study confirm the hypothesis that
the metabolism of BDP, BUD, CIC, and FP in the lung is
considerably different. This was shown in a direct compar-
ison using human precision-cut tissue slices. Unlike BUD
and FP, which are active in their parent form, both BDP
and CIC are activated in the airways by esterases to phar-
macologically active BMP or des-CIC, respectively. Results
from this study confirm previous findings showing that
BDP is hydrolyzed to BOH in the cytosol of human lung
cells [24]. However, in the current study the formation of
BOH was much faster, as was also the case in a previous
Table 5: Total amount [nmol/vial] of drug related compounds in human lung tissue slices
Incubation time [h] Parent compound Active compound Fatty acid esters Inactive metabolite
Beclomethasone  2 2.19 ± 0.83 7.88 ± 2.21 0.90 ± 0.46 0.38 ± 0.06
dipropionate2 6 0.72 ± 0.46 7.78 ± 3.80 0.50 ± 0.40 1.89 ± 0.49
24 - 2.73 ± 2.22 0.87 ± 0.96 5.72 ± 1.20
Budesonide1 2 7.32 ± 0.99 3.17 ± 2.00 -
6 8.41 ± 2.15 5.39 ± 4.03 -
24 9.04 ± 1.14 8.91 ± 5.15 -
Ciclesonide 2 6.46 ± 0.92 0.76 ± 0.2 0.40 ± 0.20 -
6 8.86 ± 1.68 2.17 ± 0.51 1.10 ± 0.73 -
24 9.53 ± 1.70 7.61 ± 1.31 7.29 ± 3.79 -
Fluticasone1 2 8.42 ± 1.26 - -
propionate 6 8.62 ± 2.20 - -
24 9.51 ± 2.22 - -
Data are presented as mean ± standard deviation (n = 9).
1Parent and active compound.
2The active compound of BDP may be overestimated as inactive 21-BMP may be included.
Table 4: Relative drug amounts [% of total UV areas] in human lung tissue slices
Incubation time [h] Parent compound Active compound Fatty acid esters Inactive metabolite
Beclomethasone  2 21.4 ± 9.8 72.1 ± 9.2 2.9 ± 1.1 3.6 ± 0.8
dipropionate2 6 9.2 ± 7.9 66.6 ± 17.7 4.4 ± 2.6 19.8 ± 10.0
24 - 26.6 ± 16.8 8.5 ± 7.8 64.9 ± 14.4
Budesonide1 2 72.2 ± 10.8 27.8 ± 10.8 -
6 64.9 ± 12.0 35.1 ± 12.0 -
24 53.6 ± 11.5 46.4 ± 11.5 -
Ciclesonide 2 85.0 ± 3.4 9.9 ± 1.4 5.1 ± 2.1 -
6 73.5 ± 4.7 17.9 ± 1.5 8.6 ± 4.1 -
24 40.0 ± 7.6 31.5 ± 2.4 28.5 ± 8.8 -
Fluticasone1 2 100 ± 0.0 - -
propionate 6 100 ± 0.0 - -
24 100 ± 0.0 - -
Data are presented as mean ± standard deviation (n = 9).
1Parent and active compound.
2The active compound of BDP may be overestimated as inactive 21-BMP may be included.Respiratory Research 2007, 8:65 http://respiratory-research.com/content/8/1/65
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study in rat lung precision-cut tissue slices [20]. The
majority of BMP was inactivated to BOH and only a small
amount of esters was formed. In contrast, a considerable
amount of des-CIC fatty acid conjugates were detected.
Experimentally it was not clear whether BMP, 21-BMP
and/or BOH was conjugated with fatty acids, because the
amounts of these metabolites were too low for further
characterization by mass spectrometry. Similar to des-
CIC, BUD formed intracellular free fatty acid esters. A pre-
requisite for the formation of fatty acid esters is the pres-
ence of a steric hindrance-free hydroxyl group at the C-21
position of the ICS. BMP, BOH, BUD, and des-CIC have a
free C-21 hydroxyl group that can be reversibly esterified.
BUD is the only parent compound with a free C-21
hydroxyl group and, therefore, esterification can start
directly once BUD has been taken up by the cell. This may
explain the high portion of fatty acid esters of BUD at early
time points. FP, which has no free C-21 hydroxyl group,
was metabolically stable in the test system because no
metabolites were detectable in the tissue and incubation
medium.
In this study, a relatively high initial concentration of ICS
was used to investigate metabolism in the lung. The con-
centration of 25 μM was the same as used in previous
studies investigating CIC metabolism in precision-cut tis-
sue slices of human and rat lungs [16,20]. In these studies,
the use of 14C-ciclesonide allowed the estimation of recov-
ery and mass balance. In the present study, although incu-
bations were carried out with non-radiolabelled CIC, the
same methods and conditions were used. The overall
metabolism rate of CIC in the current investigation was
lower than in the previous study, whereas the viability of
the cells was comparable in both studies [16]. At the end
of the incubation period, the relative percentage of des-
CIC was very similar in both studies (29% vs 32%).
The concentration of corticosteroids in the systemic circu-
lation after inhalation depends on the pharmacokinetic
properties of the drug, the formulation, and the device,
but is in general much lower than the concentration of
ICS used in the current study (25 μM). For example, in
healthy volunteers, inhalation of CIC 1280 μg via
Mean amounts of parent compounds and metabolites in lung tissue slices over time Figure 1
Mean amounts of parent compounds and metabolites in lung tissue slices over time. Initial substrate concentra-
tion: 25 μM. 1Sum of analytes = Pool for active drug detectable in human lung slices after 2, 6, and 24 h of incubation. BDP = 
beclomethasone dipropionate, BUD = budesonide, CIC = ciclesonide, FP = fluticasone propionate.
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metered-dose inhaler (MDI) resulted in a Cmax of 5.07 μg/
L (9.4 nmol/L, geometric mean) [28] and inhalation of FP
1000 μg via Diskhaler® resulted in a Cmax of 0.38 μg/L
(0.76 nmol/L, mean) [29]. However, low serum concen-
trations of corticosteroids do not necessarily mimic the
situation in the lung. After inhalation, concentrations of
ICS may be significantly higher in the lung compared with
concentrations in serum [6]. This was confirmed in three
different studies investigating the concentration of drugs
in resected lung tissue samples as well as in serum follow-
ing single inhalation of ICS. After inhalation of 1600 μg
BUD via Nebuhaler®, the mean concentration of BUD in
lung tissue obtained from resections was 5.5 nmol/kg
compared with 0.63 nmol/kg in blood plasma [30]. In a
similar study, FP concentrations of more than 20 ng/g
central lung tissue were detected in a few patients, while
the mean concentration in serum at that time was approx-
imately 0.02 ng/mL [31]. After inhalation of 1 mg BDP via
a MDI (Aerobec®), the median concentration of BMP in
bronchial tissue and serum was 4.4 ng/g tissue and 1.2 ng/
mL, respectively [33]. Although quantitative differences
cannot be excluded, the metabolic pathways of the tested
ICS in the lung should be unaffected by the chosen initial
drug concentration.
Lipophilicity and lipid conjugation are two distinct PK
parameters that can affect the absorption rate of an ICS
across pulmonary membranes and influence retention
time in the lung. Slow absorption from the lung or pul-
monary retention of the drug by some mechanism may
enhance the anti-inflammatory effects of the drug without
the unwanted systemic side effects.
The amount of FP detected in the lung tissue remained
constant during the investigated period of 2 to 24 h. The
relative distribution of FP between the tissue and the incu-
bation medium may depend on the lipophilicity and the
glucocorticoid receptor affinity of the compound. Because
the concentration of the drug is considered to be high
compared with the number of available receptor sites, the
main factor for uptake into the cells and intracellular res-
idence seems to be the lipophilicity of the drug (logD of
FP at pH 7.4 is 3.7 [20]). However, in the present study no
data for the early distribution phase were generated that
would allow a correlation between lipophilicity and dis-
tribution. The uptake of FP and CIC into human alveolar
type II epithelial cells (A549) was investigated separately
[32]. In contrast to FP, all other tested drugs were metab-
olized in the lung tissue. The active metabolite of BDP,
BMP, was further converted to fatty acid esters and mainly
to inactive polar metabolites. Over time, the concentra-
tion of drug-related compounds decreased in the tissue
and the formed polar metabolites diffused into the
medium (91.6% BOH and 8.4% BMP by 24 h).
The intracellular fatty acid conjugation of BUD and des-
CIC dramatically increased the lipophilicity of the drugs.
No fatty esters were detectable outside the cells. Des-CIC-
oleate (logD 13.0) was about 5-fold more lipophilic than
BUD-oleate (logD 12.3) [20]. The absolute drug amounts
in the lung slices at the end of the incubation period may
be correlated with their lipophilicity. CIC (logD 6.1) and
des-CIC fatty acid esters are highly lipophilic [20], which
suggests that these compounds would be retained in the
lung for a prolonged period of time. Furthermore, both
compounds are precursors of des-CIC and may thus serve
as a pool of active drug. Although the amount of active
compounds measured in the human lung tissue slices
were similar for BUD, des-CIC, and FP, the amount of
drug-related material detected in the tissue after 24 h of
incubation was higher for CIC than for the other tested
ICS.
Results from this study confirm previous findings that
both CIC and BUD reversibly form conjugates with fatty
acids [16,19,21-23]
Unlike BDP and CIC, both BUD and FP are inhaled as
active compounds. Therefore, drug exposure in the
oropharyngeal region may be much higher for BUD and
FP than for the active metabolites of BDP [33] and CIC
[34,35]. The activation of BDP in the oropharynx seems to
be fast, because similar amounts of BDP and BMP were
detected in mouth rinsing solutions directly after inhala-
tion of BDP 1000 μg via MDI [33]. In contrast, the activa-
tion of CIC in the oropharynx is very low. Only traces of
des-CIC were detected in mouth rinsing solutions directly
after inhalation of CIC 800 μg via MDI [34,35]. Higher
concentrations of BMP compared to des-CIC in the
oropharynx might be explained by differences in the
velocity of BMP and des-CIC formation as observed in the
present study. Administration of CIC as an inactive parent
compound and the low oropharyngeal deposition of des-
CIC may explain the low incidence of oropharyngeal side
effects observed in clinical studies [36].
Conclusion
In summary, when developing ICS it is necessary to con-
sider the overall balance between safety and efficacy. In
this study we saw clear differences between the investi-
gated ICS regarding the residence time of the drugs within
the lung tissue slices, because of their different metabo-
lism, lipophilicity, and ability to form lipid conjugates.
Highly lipophilic drugs will likely contribute to a high rate
of absorption within the lung. Once in the lung, reversible
fatty acid conjugation may prolong the local anti-inflam-
matory activity by slowly releasing active drug from the
fatty acid ester depot. Of the currently available ICS, only
CIC and BUD undergo lipid conjugation. This conceptRespiratory Research 2007, 8:65 http://respiratory-research.com/content/8/1/65
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supports the once-daily dosing efficacy of these drugs that
was observed in clinical studies [37,38].
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